Nanobiotix Files January 2025 6-K Report
Ticker: NBTX · Form: 6-K · Filed: Jan 10, 2025 · CIK: 1760854
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Nanobiotix filed its Jan 2025 6-K, standard foreign private issuer update.
AI Summary
Nanobiotix S.A. filed a Form 6-K on January 10, 2025, for the month of January 2025. The company, headquartered in Paris, France, is a foreign private issuer and is submitting its report under the Securities Exchange Act of 1934. Nanobiotix is incorporated in I0 and its fiscal year ends on December 31.
Why It Matters
This filing provides routine updates for Nanobiotix S.A. as a foreign private issuer, informing investors about their ongoing reporting obligations.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific material events or financial disclosures.
Key Players & Entities
- Nanobiotix S.A. (company) — Filer of the Form 6-K
- Paris, France (location) — Company headquarters
- 001-39777 (company) — SEC File Number
- 20-F (document) — Annual report form
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the company has made or will make public in its home country.
When was this Form 6-K filed?
This Form 6-K was filed on January 10, 2025.
What is Nanobiotix S.A.'s principal executive office address?
Nanobiotix S.A.'s principal executive office is located at 60 Rue de Wattignies, 75012 Paris, France.
Does Nanobiotix S.A. file annual reports under Form 20-F?
Yes, Nanobiotix S.A. indicates by check mark that it files or will file annual reports under cover of Form 20-F.
What is the SIC code for Nanobiotix S.A.?
The Standard Industrial Classification (SIC) code for Nanobiotix S.A. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2025-01-10 06:05:46
Filing Documents
- f6k_010925.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-25-000146.txt ( ) — 13KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Nanobiotix S.A. (Registrant) Date: January 9, 2025 /s/ Bart Van Rhijn Bart Van Rhijn Chief Financial Officer